Cargando…

Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity

BACKGROUND AND AIMS: Epicardial adipose tissue (EAT), the visceral fat depot of the heart, is a modifiable cardio-metbolic risk factor and therapeutic target. Semaglutide and dulaglutide, glucagon-like peptide-1 (GLP-1) receptor agonists, are indicated for the treatment of type 2 diabetes mellitus (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iacobellis, Gianluca, Villasante Fricke, Alexandra C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Clinical Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069837/ https://www.ncbi.nlm.nih.gov/pubmed/32190806 http://dx.doi.org/10.1210/jendso/bvz042

Ejemplares similares

Epicardial Adipose Tissue: Clinical Biomarker of Cardio-Metabolic Risk
por: Villasante Fricke, Alexandra C., et al.
Publicado: (2019)

Semaglutide therapy decreases epicardial fat inflammation and improves psoriasis severity in patients affected by abdominal obesity and type-2 diabetes
por: Malavazos, Alexis Elias, et al.
Publicado: (2023)

The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal
por: Malkin, Samuel J. P., et al.
Publicado: (2022)

Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada
por: Johansen, Pierre, et al.
Publicado: (2019)

A Comparative Study of Epicardial Fat Thickness and its Association with Abdominal Visceral Fat Thickness in Obese and Nonobese Type 2 Diabetes Subjects
por: Jain, Siddharth, et al.
Publicado: (2015)

Relation of Epicardial Fat Thickness with Carotid Intima-Media Thickness in Patients with Type 2 Diabetes Mellitus
por: Cetin, Mustafa, et al.
Publicado: (2013)

Evaluation of the long‐term cost‐effectiveness of once‐weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
por: Viljoen, Adie, et al.
Publicado: (2018)

The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
por: Malkin, Samuel J. P., et al.
Publicado: (2019)

Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
por: Iijima, Takahiro, et al.
Publicado: (2023)

Comparison of the injection‐site experience of the starting doses with semaglutide and dulaglutide: A randomized, double‐blind trial in healthy subjects
por: Snitker, Søren, et al.
Publicado: (2021)

Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China
por: Ruan, Zhen, et al.
Publicado: (2022)

Epicardial fat thickness and oxidative stress parameters in patients with subclinical hypothyroidism
por: Aydogdu, Ali, et al.
Publicado: (2017)

Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study
por: Barrett, Annabel, et al.
Publicado: (2023)

Corrigendum to Effects of switching from liraglutide to semaglutide or dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Publicado: (2023)

Epicardial adipose tissue in contemporary cardiology
por: Iacobellis, Gianluca
Publicado: (2022)

Aging Effects on Epicardial Adipose Tissue
por: Iacobellis, Gianluca
Publicado: (2021)

A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK
por: Johansen, Pierre, et al.
Publicado: (2020)

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses
por: Pratley, Richard E, et al.
Publicado: (2020)

An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg
por: Pratley, Richard E., et al.
Publicado: (2021)

The relationship between epicardial fat thickness and gestational diabetes mellitus
por: Nar, Gökay, et al.
Publicado: (2014)

Effect of Orally Administered Semaglutide Versus Dulaglutide on Diabetes-Related Quality of Life in Japanese Patients with Type 2 Diabetes: The PIONEER 10 Randomized, Active-Controlled Trial
por: Ishii, Hitoshi, et al.
Publicado: (2021)

Epicardial Fat Thickness as Cardiovascular Risk Factor and Therapeutic Target in Patients with Rheumatoid Arthritis Treated with Biological and Nonbiological Therapies
por: Lima-Martínez, Marcos M., et al.
Publicado: (2014)

Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
por: Gæde, Peter, et al.
Publicado: (2019)

Assessing patient PREFERence between the dulaglutide pen and the semaglutide pen: A crossover study (PREFER)
por: Matza, Louis S., et al.
Publicado: (2019)

Correlation Between Epicardial Fat Thickness by Echocardiography and Other Parameters in Obese Adolescents
por: Kim, Sung Jin, et al.
Publicado: (2012)

Evaluation of Electrocardiographic T-peak to T-end Interval in Subjects with Increased Epicardial Fat Tissue Thickness
por: Kaplan, Ozgur, et al.
Publicado: (2015)

Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
por: Newsome, Philip, et al.
Publicado: (2019)

Evaluation of serum endocan levels in relation to epicardial fat tissue thickness in metabolic syndrome patients
por: Boyuk, Banu, et al.
Publicado: (2020)

Increased Epicardial Adipose Tissue Thickness in Type 2 Diabetes Mellitus and Obesity
por: Song, Do Kyeong, et al.
Publicado: (2015)

Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study
por: Jain, Akshay B., et al.
Publicado: (2020)

Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China
por: Hu, Shanshan, et al.
Publicado: (2022)

Evaluation oF Epicardial Fat and Carotid Intima-Media Thickness in Obese Children
por: Elshorbagy, Hatem Hamed, et al.
Publicado: (2016)

Epicardial Fat Tissue Thickness in Preeclamptic and Normal Pregnancies
por: Can, Mehmet Mustafa, et al.
Publicado: (2012)

The Relation of Androgenetic Alopecia Severity with Epicardial Fat Thickness
por: Colgecen, Emine, et al.
Publicado: (2016)

The relation between epicardial fat thickness and metabolic syndrome
por: Balta, Sevket, et al.
Publicado: (2016)

Measurement of Epicardial Fat Thickness by Echocardiography Presents Challenges
por: Gulgun, Mustafa, et al.
Publicado: (2016)

Fetal Epicardial Fat Thickness: Its Role as Marker for Gestational Diabetic Mellitus
por: Singh, Amandeep, et al.
Publicado: (2023)

Is there a relationship between epicardial fat tissue thickness and Tp-Te/QT ratio in healthy individuals?
por: Yılmaz, Mücahid, et al.
Publicado: (2020)

Cost of Achieving HbA1c Treatment Targets and Weight Loss Responses with Once-Weekly Semaglutide Versus Dulaglutide in the United States
por: Wilkinson, Lars, et al.
Publicado: (2018)

Epicardial fat thickness and severity of coronary heart disease in patients with diabetes mellitus type II
por: Nasri, Ali, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_bmkrpl7ekv611vn8kf5vi6ke1v